MAP3K8/Tpl2/COT Antibody

ELISA: MAP3K8/Tpl2/COT Antibody [23930002]

Product Discontinued

MAP3K8/Tpl2/COT Antibody Summary

• Immunogen: This antibody is specific for the Middle Region of the target protein.
• Specificity: This product is specific for Human MAP3K8.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MAP3K8
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:250-1:2000
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:5000-1:20000
• Application Notes: This antibody is useful in ELISA, Western Blot, Immunohistochemistry-Paraffin and Immunoprecipitation.

Reactivity Notes

Human.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM Potassium Phosphate (pH 7.0) and 0.15M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for MAP3K8/Tpl2/COT Antibody

• Cancer Osaka thyroid oncogene
• c-COT
• cot (cancer Osaka thyroid) oncogene
• COT
• COTMEKK8
• EC 2.7.11.25
• EST
• ESTF
• ESTFLJ10486
• Ewing sarcoma transformant
• MAP3K8
• mitogen-activated protein kinase kinase kinase 8
• Proto-oncogene c-Cot
• proto-oncogene serine/threoine protein kinase
• Serine/threonine-protein kinase cot
• TPL2
• Tpl-2
• Tumor progression locus 2
• tumor progression locus-2

Background

TPL-2, a MEK kinase is essential for TLR4 activation of the ERK mitogen-activated protein kinase cascade in lipopolysaccharide (LPS)-stimulated macrophages. Interaction with p105 is required to maintain TPL-2 metabolic stability and also negatively regulates TPL-2 MEK kinase activity (1). The NF-kappaB1 gene encodes a larger precursor protein, p105, from which p50 is produced constitutively by proteasome-mediated removal of the p105 carboxy terminus. TPL-2 , which is homologous to MAP-kinase-kinase kinases in its catalytic domain, forms a complex with the carboxy terminus of p105. TPL-2 was originally identified, in a carboxy-terminal-deleted form, as an oncoprotein in rats and is more than 90% identical to the human oncoprotein COT. Expression of TPL-2 results in phosphorylation and increased degradation of p105 while maintaining p50 production. This releases associated Rel subunits or p50-Rel heterodimers to generate active nuclear NF-kappaB. Furthermore, kinase-inactive TPL-2 blocks the degradation of p105 induced by tumor-necrosis factor-alpha. TPL-2 is therefore a component of a new signaling pathway that controls proteolysis of NF-kappaB1 p105 (2).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MAP3K8/Tpl2/COT Antibody (23930002)(2)

Publications using 23930002

• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Bioinformatics

• Gene Symbol: MAP3K8
• Entrez:
  • 1326(Human)
• Uniprot:
  • P41279()